Maxigen Biotech Inc. (TPE:1783)

Maxigen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	702.88	639.05	431.08	790.95	513.31	209.76
Short-Term Investments	-	-	-	8.82	13.84	-
Cash & Short-Term Investments	702.88	639.05	431.08	799.76	527.15	209.76
Cash Growth	45.48%	48.24%	-46.10%	51.72%	151.31%	-50.03%
Accounts Receivable	87.22	103.91	88.31	98.86	109.95	94.91
Other Receivables	0.3	-	8.75	1.42	4.76	7.32
Receivables	87.52	103.91	97.06	100.27	114.71	102.23
Inventory	74.09	75.76	85.32	75.41	80.63	88.02
Prepaid Expenses	11.88	9.82	4.52	15.41	47.78	18.62
Other Current Assets	1.82	1.79	1.58	2.39	13.29	13.43
Total Current Assets	878.18	830.33	619.56	993.25	783.55	432.06
Property, Plant & Equipment	432.99	430.36	424.18	434.62	465.45	481.52
Long-Term Investments	368.26	311.31	432.8	-	-	-
Other Intangible Assets	0.1	0.13	0.49	1.16	1.83	1.67
Long-Term Deferred Tax Assets	1.63	2.55	5.83	3.19	0.38	1.07
Other Long-Term Assets	15.18	7.81	10.13	15.5	13.97	40.15
Total Assets	1,696	1,582	1,493	1,448	1,265	956.47
Accounts Payable	56.56	49.98	17.17	35.94	40.15	33
Accrued Expenses	61.04	72.07	64.63	55.35	40.35	30.21
Current Portion of Leases	-	-	-	-	2.36	2.49
Current Income Taxes Payable	37.28	25.52	24.47	27.17	9.28	8.69
Current Unearned Revenue	15.13	22.93	1.34	4.25	11.13	3.76
Other Current Liabilities	39.96	35.37	23.78	28.79	12.8	8.42
Total Current Liabilities	209.98	205.87	131.37	151.5	116.07	86.58
Long-Term Leases	-	-	-	-	7.28	9.64
Long-Term Deferred Tax Liabilities	0.81	0.93	0.49	0.55	-	-
Other Long-Term Liabilities	7.42	0.56	0.02	0.02	0.12	0.02
Total Liabilities	218.2	207.36	131.88	152.07	123.47	96.24
Common Stock	896.76	891.63	889.34	846.99	769.99	694.65
Additional Paid-In Capital	327.69	326.93	296.1	281.9	264.39	89.18
Retained Earnings	391.07	344.12	244.46	169.8	110.3	79.38
Comprehensive Income & Other	-137.38	-187.56	-68.79	-3.04	-2.96	-2.99
Total Common Equity	1,478	1,375	1,361	1,296	1,142	860.23
Shareholders' Equity	1,478	1,375	1,361	1,296	1,142	860.23
Total Liabilities & Equity	1,696	1,582	1,493	1,448	1,265	956.47
Total Debt	-	-	-	-	9.64	12.13
Net Cash (Debt)	702.88	639.05	431.08	799.76	517.51	197.63
Net Cash Growth	45.48%	48.24%	-46.10%	54.54%	161.86%	3.72%
Net Cash Per Share	7.80	7.12	4.82	8.95	6.12	2.45
Filing Date Shares Outstanding	89.68	89.16	88.93	88.93	88.93	80.23
Total Common Shares Outstanding	89.68	89.16	88.93	88.93	88.93	80.23
Working Capital	668.21	624.47	488.19	841.75	667.49	345.47
Book Value Per Share	16.48	15.42	15.30	14.57	12.84	10.72
Tangible Book Value	1,478	1,375	1,361	1,294	1,140	858.55
Tangible Book Value Per Share	16.48	15.42	15.30	14.56	12.82	10.70
Land	133.23	133.23	133.23	133.23	133.23	133.23
Buildings	310.62	310.48	307.74	303.11	302.48	301.8
Machinery	188.99	181.24	160.52	149.88	162	141.51
Construction In Progress	21.89	20.08	17.67	21.6	18.79	26.03
Leasehold Improvements	13.43	13.43	18.91	18.91	23.7	21.86

Source: S&P Global Market Intelligence. Standard template. Financial Sources.